New hope for transplant patients: study aims to block dangerous late-stage virus
Disease control
Recruiting now
This study tests whether giving CytoGam® (CMV immunoglobulin) after standard antiviral treatment can prevent late CMV infection in high-risk kidney or liver transplant recipients. About 80 participants who are CMV-negative but receive an organ from a CMV-positive donor will be en…
Phase: PHASE4 • Sponsor: Camille N. Kotton, MD • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC